Hyperemesis Gravidarum Treatment Delivered To You – Antai Hospital

Hyperemesis Home Treatment: Delivered To You

Introduction

During pregnancy, up to 80% of women experience nausea and/or vomiting (N/V). For the majority of women, N/V resolves by the 16th week of pregnancy. A severe and prolonged form of N/V, hyperemesis gravidarum (HG), affects 0.3–2% of pregnancies. The criteria that define HG include dehydration, ketonuria, and more than 5% weight loss (Nelson-Piercy 1998) (McCarthy et al. 2014). HG is the most common indication for hospital admission in the first 20 weeks of pregnancy. Although it usually occurs between weeks 4 and 9 of pregnancy and resolves by mid-gestation, between 15 and 20% of women continue to experience symptoms until the third trimester and 5% through delivery. Women with HG often present with increased blood urea nitrogen and hematocrit and, in 15–25% of cases, hyponatremia, hypokalemia, and hypochloremia.

Electrolyte abnormalities are corrected with intravenous replacement fluids; however, in severe cases, sustained weight loss requires enteral or total parenteral nutrition.. Between 15 and 50% of patients with HG have elevated serum aminotransferases and total bilirubin. HG is a clinical diagnosis; however, tools such as the Pregnancy Unique Quantification of Emesis (PUQE) score or Rhodes index have been used to assess the severity of symptoms in research studies. HG is a diagnosis of exclusion, and alternative diagnoses should be considered when the N/V begins after 9 weeks of gestation or if bilious emesis, fever, abdominal pain, headache, focal neurological findings, leukocytosis, or hypertension are present. Comorbid conditions, most commonly reflux, should also be evaluated and treated (Gideon et al. 2009). Women presenting with HG are evaluated with serial measures of maternal weight, orthostatic blood pressures, heart rate, electrolytes, urine ketones, and an obstetric ultrasound if not previously obtained.

 

Maternal, foetal, and child outcomes associated with HG 

Maternal outcomes 

Women with HG are at risk for complications from excessive vomiting including hematemesis and from dehydration including dizziness and syncope. More severe complications include Wernicke’s encephalopathy, central pontine myelinolysis, and peripheral neuropathy due to vitamin B6 or B12 deficiency. Women with HG are at increased risk for developing secondary depression and anxiety which typically resolve with remission of N/V by the third trimester of pregnancy. In a survey of women’s experiences with HG, 15.2% women had voluntarily terminated at least one pregnancy. 

Fetal outcomes 

HG has been associated with increased rates of low birth weight and small for gestational age infants. Further, some studies found that stratification by severity of HG (defined by losing greater than 5% of body weight) demonstrated that women with severe HG were more likely to have babies with smaller birth weight and in the <10th percentile at birth compared to women who maintained 95% of their body weight. There are also observations of cardiac malformations in women with severe N/V.

Child outcomes 

Few data have been published on long-term outcomes for children born to mothers with HG. One study showed 20% lower insulin sensitivity in pre-pubertal children of mothers with severe HG compared to children with mothers without HG. A retrospective case control study of adults showed an increase in psychological and behavioural disorders in a composite mental health outcome measure, but individual analyses did not show increases in depression, anxiety, or bipolar disorders. 

Cause

The increased level of free β-hCG in women with HG is known as the secondary cause for hyperemesis gravidarum. The primary cause behind HG is the presence of abnormal M1-receptors that are situated in effector glands and several organs of the body. This receptors bind with the free hCG and causes a phenomenon known as central sensitization, a systemic hypersensitization effect throughout the gestation period, and without treatment or intervention, will last until hCG is no longer systemically present.

Remote Treatment For Your Hyperemesis Gravidarum

Our effective treatment for HG is known as our in-house HCG-Desensitizer and is offered to our HG patients all over the world, the medication is non-toxic and is not teratogenic as well. Symptoms subside within a day or two, however it is best received before or during the early stages of pregnancy to observe the most effective outcome.

Antai Hospital is now offering a home-based treatment for your Hyperemesis Gravidarum condition, by directly delivering it to your home via mail, where you can now observe effective recovery at the comfort of your own home. 

Terms that need fulfilling include:

1. You will need to appoint a medical staff such as a nurse or doctor that can administer the treatment via injections for you, and can accurately and professionally observe your symptoms and reactions, if any.

2. You will need to make a full payment of the treatment cost, in order for us to directly mail the treatment to you.

Antai Hospital’s Commitment

Antai Hospital’s full refund policy for the miscarriage prevention treatments we provide should already be the best guarantee for a healthy pregnancy. Patients should rest assured, can and should go about their everyday life, focusing their diet on vegetables, beans, celery, and other fiber-rich foods. Besides that, an active lifestyle of yoga and swimming should also be incorporated to help relieve stress and increase blood circulation, which is beneficial for the fetus’s development and the mother’s health. With our assurance, a healthy lifestyle, and peace of mind, you can go through a healthy pregnancy with no complications.

Recurrent miscarriages are no doubt a heavy blow to the patient’s physical and mental health. All we can do is to help ease the burden and decrease your trauma, to slowly help you overcome the anxiety with the love and care that we provide at Antai Hospital.

Trust in Antai Hospital and trust in yourself, your pregnancy is our priority.